The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.Board of Regents, University of Texas Syste
In order to improve the aqueous solubility and dissolution of Tacrolimus (TAC), amorphous solid disp...
Pharmaceutical compositions in form of nanoparticles comprising a composite material, consisting of ...
textPoorly water soluble drugs have been manipulated to make them more soluble, increasing the bioav...
The present invention includes compositions and methods for making and using a rapid dissolving, hig...
Inhalable compositions are described. The inhalable compositions comprise one or more respirable agg...
Tacrolimus (TAC) has exhibited promising therapeutic potential in the treatment of pulmonary arteria...
Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or ...
Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or ...
The present invention provides a method of improving the efficiency of absorption into the bloodstre...
The present invention includes compositions and methods for treating and delivering medicinal formul...
The present invention relates to formulations for delivery of drugs to the respiratory tract, especi...
Pulmonary drug delivery has recently gained much importance in the health care research area as it e...
textBioavailability enhancement of poorly water soluble active pharmaceutical ingredients (API) is k...
In an effort to improve lymphatic targeting efficiency and reduce the toxicity of tacrolimus, the em...
The use of nanoparticles as drug carriers for pulmonary delivery of medicines is advantageous as the...
In order to improve the aqueous solubility and dissolution of Tacrolimus (TAC), amorphous solid disp...
Pharmaceutical compositions in form of nanoparticles comprising a composite material, consisting of ...
textPoorly water soluble drugs have been manipulated to make them more soluble, increasing the bioav...
The present invention includes compositions and methods for making and using a rapid dissolving, hig...
Inhalable compositions are described. The inhalable compositions comprise one or more respirable agg...
Tacrolimus (TAC) has exhibited promising therapeutic potential in the treatment of pulmonary arteria...
Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or ...
Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or ...
The present invention provides a method of improving the efficiency of absorption into the bloodstre...
The present invention includes compositions and methods for treating and delivering medicinal formul...
The present invention relates to formulations for delivery of drugs to the respiratory tract, especi...
Pulmonary drug delivery has recently gained much importance in the health care research area as it e...
textBioavailability enhancement of poorly water soluble active pharmaceutical ingredients (API) is k...
In an effort to improve lymphatic targeting efficiency and reduce the toxicity of tacrolimus, the em...
The use of nanoparticles as drug carriers for pulmonary delivery of medicines is advantageous as the...
In order to improve the aqueous solubility and dissolution of Tacrolimus (TAC), amorphous solid disp...
Pharmaceutical compositions in form of nanoparticles comprising a composite material, consisting of ...
textPoorly water soluble drugs have been manipulated to make them more soluble, increasing the bioav...